SJG-136

DB11965InvestigationalSmall molecule

SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and Secondary Myelodysplastic Syndromes,...

Mechanism: Pharmacologically active on Proto-oncogene tyrosine-protein kinase Src
Curator reviewed
Formula / weight: C₃₁H₃₂N₄O₆ · 556.619 g/mol (avg)
Code names: BN-2629 · NSC-694501 · SG-2000 · SP-2001 · UP-2001

Resolves to

Compound

UNIIKT0ZQ64X1ACAS232931-57-6ChEMBLCHEMBL16498PubChem393111

Structure

InChIKeyRWZVMMQNDHPRQD-SFTDATJTSA-NSMILESCOC1=CC2=C(C=C1OCCCOC1=CC3=C(C=C1OC)C(=O)N1CC(=C)C[C@H]1C=N3)N=C[C@@H]1CC(=C)CN1C2=O

Targets

P12931SRC

Transporters

P33527ABCC1P08183ABCB1Q9UNQ0ABCG2

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3TransportersSubstrate / inhibitor direction, not just membership

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with SJG-136, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In